Samyang CEO, Lee Young-Joon, and LG Chem’s Life Sciences company head, Son Ji-Woong, signed the licensing agreement for NanoReady at LG Science Park, Seoul. Credit: Samyang Holdings / PRNewswire.

Samyang has entered into a strategic partnership agreement with LG Chem to develop new cancer therapeutics using Samyang’s technology, NanoReady.

Samyang will provide LG Chem non-exclusive rights to the NanoReady technology, along with a supply of its key components.

LG Chem will use the technology for the development of innovative mRNA-based cancer therapeutics with maximised therapeutic efficacy.

In return, the company will make an upfront payment and a series of milestone-linked payments to Samyang.

Samyang Holdings Biopharm Division CEO Young-Joon Lee stated: “LG Chem has exceptional research and development expertise in innovative drug development and a number of promising new drug pipelines.

“Taking this recent deal as a driving force, we will continue to strengthen our partnership with LG Chem.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“By leveraging the capabilities of the two companies, we hope to accelerate the development of innovative cancer therapy to significantly improve the lives of suffering cancer patients.”

The company stated that NanoReady provides high versatility to different mRNA molecules.

When combined with mRNA therapeutic molecules developed by LG Chem, the pre-made drug delivery formulation helps to simplify and improve the combination process.

This is expected to shorten the development time of new drugs and to support personalised treatments.

LG Chem Life Sciences company head Ji-Woong Son said: “We hope to maximise success through active collaboration between the two companies, with the aim to provide innovative mRNA-based cancer therapeutics to patients worldwide.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.